Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-317.42M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -64.12% |
| Return on Assets (Trailing 12 Months) | -56.75% |
| Current Ratio (Most Recent Fiscal Quarter) | 16.83 |
| Quick Ratio (Most Recent Fiscal Quarter) | 20.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.17 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.02 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.97 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.86 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 142.26M |
| Free Float | 97.59M |
| Market Capitalization | $1.31B |
| Average Volume (Last 20 Days) | 2.80M |
| Beta (Past 60 Months) | 1.08 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.14% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.68% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |